Pasireotide: A Novel Treatment for Tumor-Induced Hypoglycemia Due to Insulinoma and Non-Islet Cell Tumor Hypoglycemia.

Tumor-induced hypoglycemia is a serious disorder most commonly caused by insulinoma or non-islet cell tumor hypoglycemia (NICTH). The hypoglycemia can be severe and refractory to conventional therapy, leading to significant morbidity and mortality. The objective of this work is to describe a series of challenging cases in which refractory, tumor-induced hypoglycemia was shown to respond to the use of pasireotide, a second-generation somatostatin receptor ligand.

DISEASE to EASE: Paradigm shift in clinical approach.

The high demands of contemporary medical practice have minimized the patient-physician contact with less or no time for Empathy. Unconsciously, our mind is set to focus on "disease" and often patients are referred as "cases." Where there is a rising concern of physician fatigue and burn out, there is equal concern of losing the component of "being humane" in the busy era of modern medical practices.